Comparative single dose pharmacokinetics and metabolism of racemic primaquine and its enantiomers in human volunteers. (August 2022)

• Record Type: Journal Article
• Authors: Khan, Washim; Wang, Yan-Hong; Chaurasiya, Narayan D.; Nanayakkara, NP Dhammika; Herath, HM Bandara; Harrison, Kerri A.; Dale, Gray; Stanford, Donald A.; Dahl, Eric P.; McChesney, James D.; Gul, Waseem; ElSohly, Mahmoud A.; Khan, Shabana I.; Fasinu, Pius S.; Khan, Ikhlas A.; Tekwani, Babu L.; Walker, Larry A.
• Is Part Of: Drug metabolism and pharmacokinetics. Volume 45(2022)
• Publication Date: 2022-08
• Subjects: Primaquine -- Racemate -- Enantiomers -- Carboxyprimaquine -- Primaquine-N-Carbamoyl-glucuronide -- Pharmacokinetics -- UHPLC-MS/MS; Drugs -- Metabolism -- Periodicals; Pharmacokinetics -- Periodicals; 615.7
• DOI: 10.1016/j.dmpk.2022.100463
• Languages: English
• ISSNs: 1347-4367

Abstract

Abstract: Primaquine (PQ) is a racemic drug used in treatment of malaria for six decades. Recent studies suggest that the two enantiomers of PQ are differentially metabolized in animals, and this results in different pharmacological and toxicological profiles. The current study characterizes the pharmacokinetic (PK) properties, metabolism and tolerability of the individual enantiomers of PQ in healthy human volunteers with normal glucose-6-phosphate dehydrogenase (G6PD) activity. Two cohorts (at two dose levels), each with 18 subjects, participated in three study arms in a crossover fashion: a single dose of the (−)- R enantiomer (RPQ), a single dose of the (+)- S enantiomer (SPQ), and a single dose of racemic PQ (RSPQ). PQ and its key metabolites carboxyprimaquine (cPQ) and PQ-N-carbamoyl glucuronide (PQ-N-CG) were analyzed. Clear differences were observed in PK and metabolism of the two enantiomers. Relative PQ exposure was higher with SPQ as compared to RPQ. PQ maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve were higher for SPQ, while the apparent volume of distribution and total body clearance were higher for RPQ. Metabolism of the two enantiomers showed dramatic differences: plasma PQ-N-CG was derived solely from SPQ, while RPQ was much more efficiently converted to cPQ than was SPQ. Cmax of cPQ and PQ-N-CG were 10 and 2 times higher, respectively, than the parent drugs. The study demonstrates that the PK properties of PQ enantiomers show clear differences, and metabolism is highly enantioselective. Such differences in metabolism suggest potentially distinct toxicity profiles in multi-dose regimens, especially in G6PD-deficient subjects. Graphical abstract: Image 1